"versionIdentifier","rationale","id","uuid:ID","instanceType"
"2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","96f5c2cb-cc30-4e76-b64a-5d92a64d871f","StudyVersion"
